Taking consideration of this point, Dolcetti lab encapsulated E7 peptide and glycolipid ligand α‐galactosylceramide (αGC) in the Clec9a‐targeted nanoemulsion, to explore the feasibility of enhanced anti‐tumor immunity driven by NKT cells.[55] A single intravenous administration of the designed vaccine nanoformulation enhanced the activation of cDC1s, iNKT cells, NKT cells, and functional effector CD8+ T cells, resulting in long‐term TC‐1 tumor suppression in a therapeutic model. The gene discussed is CD8A; the disease is neoplasm.